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ARTICLE
A Physiologically-Based Pharmacokinetic Model for 
Targeting Calcitriol-Conjugated Quantum Dots to 
Inflammatory Breast Cancer Cells
James Forder1, Mallory Smith1, Margot Wagner1, Rachel J. Schaefer2, Jonathon Gorky3, Kenneth L. van Golen2, Anja Nohe2 and 
Prasad Dhurjati1,*
Quantum dots (QDs) conjugated with 1,25 dihydroxyvitamin D3 (calcitriol) and Mucin-1 (MUC-1) antibodies (SM3) have been 
found to target inflammatory breast cancer (IBC) tumors and reduce proliferation, migration, and differentiation of these 
tumors in mice. A physiologically-based pharmacokinetic model has been constructed and optimized to match experimental 
data for multiple QDs: control QDs, QDs conjugated with calcitriol, and QDs conjugated with both calcitriol and SM3 MUC1 
antibodies. The model predicts continuous QD concentration for key tissues in mice distinguished by IBC stage (healthy, 
early-stage, and late-stage). Experimental and clinical efforts in QD treatment of IBC can be augmented by in silico simula-
tions that predict the short-term and long-term behavior of QD treatment regimens.
Inflammatory breast cancer (IBC) is an aggressive form of 
cancer, which makes up ~  1–5% of breast cancer cases 
but accounts for 10% of breast cancer deaths annually in 
the United States.1 Often, this form of cancer is difficult to 
diagnose and is typically not recognized until it has pro-
gressed to stage III or IV.1 The median survival time after 
diagnosis is <15 months with recurrence rates as high as 
50%.2 Traditional treatment plans consisting of surgery 
and localized radiotherapy result in a <5% survival rate be-
yond 5  years, the lowest survival rate of any breast can-
cer subtype.2 With more advanced treatment combining 
multiple-targeting approaches, IBC still only has 5-year 
and 10-year disease-free survival rates of <45% and 20%, 
respectively.2
IBC is a rapidly progressing and highly metastatic dis-
ease with a younger age of onset relative to other types of 
breast cancer.2 Typical symptoms include erythema, edema, 
and thickening or pitting of the breast, which is caused by 
tumor emboli blocking dermal lymph drainage.3 By the time 
discernable symptoms are present, IBC is already locally 
advanced as the breast cancer cells have grown into sur-
rounding structures and sometimes to distant metastasis 
sites, commonly in the bone, lungs, and skin.4,5 These non-
specific symptoms, especially in absence of the stereotyp-
ical lump formation, are often misidentified as an infection 
or rash leading to IBC being misdiagnosed as mastitis or 
generalized dermatitis, delaying the treatment of the under-
lying cancer.1,2 As a result, when diagnosed with IBC, almost 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Recent studies have indicated that calcitriol has 
beneficial effects against SUM149 inflammatory breast 
cancer (IBC) proliferation, migration, and differentiation. 
Although preliminary studies on calcitriol-conjugated 
quantum dots (QDs) injected into mice with IBC have 
been encouraging, no model exists to predict the distri-
bution of these QDs.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  The study addresses the parameters, connectivity, 
and mathematical relationships needed to construct a 
model to predict dynamic QD distribution in mice with 
IBC.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  A physiologically-based pharmacokinetic model frame-
work has been constructed and validated for multiple QDs, 
notably SM3 calcitriol QDs. Continuous QD concentration 
estimates for key tissues can be generated, with the ability for 
adjustments to cover a broad range of patient characteristics.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
✔  The PBPK model provides a framework to guide or com-
plement both experimental and clinical endeavors in QD 
treatment of IBC and to infer behavior of experiments not 
performed. With additional data, the model has the potential 
to provide further mechanistic understanding of the disease.
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all women are lymph node–positive with approximately one-
third having distant metastases.2
Current treatment involves a multiple-targeting approach 
due to the aggressive nature of IBC. Hormone treatment 
is ineffective for many patients with IBC because approx-
imately one-third of IBC diagnoses are triple-negative.1,2 
Instead, current treatment plans involve systemic chemo-
therapy followed by a mastectomy to remove the tumor and 
surrounding tissue and finally localized radiotherapy.1,2 In 
addition to this, patients with IBC are often prescribed vi-
tamin D supplements due to the vitamin’s beneficial effect 
on reducing the cancer’s metastasis rate.6 Despite this mul-
timodality treatment plan, prognosis for patients with IBC 
is poor. Researchers are pursuing an improved treatment 
method for IBC, ideally one that could prevent tumor cell 
migration as well as preventing or disrupting the formation 
of tumor emboli.2
A potential new therapeutic is the active form of vitamin 
D, 1,25 dihydroxyvitamin D3 (calcitriol). Calcitriol is known to 
modulate calcium and phosphate homeostasis to maintain 
bone health; it is most biologically active in tissues positive 
for vitamin D receptors, including organs, such as the kidney 
and intestines, as well as bone and the parathyroid gland.7,8 
Recently, vitamin D has been demonstrated to be a regulator 
of breast cancer cell proliferation, invasion, migration, differ-
entiation, and apoptosis in vitro. The antiproliferative effects 
are thought to be a result of calcitriol blocking the mitogenic 
effects of insulin-like growth factor I through downregulation 
of its receptors, causing the G1 phase of the cell cycle to 
pause.9 In addition, it was found that SUM149 cells exposed 
to calcitriol exhibited a decreased ability to migrate, invade, 
and form tumor emboli, leading to decreased metastasis in 
vivo.10,11 However, previous studies have required toxic dos-
ages of calcitriol (over 0.50 μg) to have a significant effect, 
which would lead to hypercalcemia.10–12 Therefore, targeting 
methods are required to reach desired levels of calcitriol at 
treatment sites without having an excess of calcitriol in the 
rest of the body.
Quantum dots (QDs) conjugated to calcitriol have previ-
ously been used to examine the distribution of calcitriol both 
in vitro and in vivo.10,11 QDs are semiconductor nanoparticles 
around 15 nm in diameter, which can be used for fluorescent 
imaging under UV light and have a variety of surface chem-
istries that are compatible with living systems. They localize 
in the liver, lymph nodes, kidneys, and spleen in mice, with 
some effects on distribution from the polymer surface chem-
istry (conjugated with carboxyl groups in this case).10 To use 
calcitriol QDs for direct imaging of live cells, QDs are conju-
gated to calcitriol using an esterification reaction to produce 
calcitriol QDs (CalQDs).10,11 To avoid hypercalcemia and po-
tential toxicity, these CalQDs can be manipulated to target 
tumor sites. Unlike other forms of breast cancer, IBC cells 
overexpress a hypoglycosylated form of Mucin-1 (MUC1), a 
glycoprotein that is expressed on the apical surface of ep-
ithelial cells. Recently, Schaefer et al.10,11 have proposed a 
therapeutic method conjugating SM3 MUC1 antibodies with 
CalQDs (SM3 CalQDs). In their studies, Schaefer et al.10,11 
used florescent imaging to measure the accumulation of 
SM3 CalQDs in various organs as well as tumor tissue in 
mice with SUM149 IBC tumors. The SM3 CalQDs were 
shown to target MUC1 overexpressing IBC cells, identify 
localization of IBC tumor emboli, and act as a vehicle to ad-
minister calcitriol more directly to affected areas, mitigating 
hypercalcemia and other negative side effects.
To better elucidate the details of the distribution of SM3 
CalQDs as well as finding an adequate dosing regimen, we 
look to create a physiologically-based pharmacokinetic 
(PBPK) model. However, one of the challenges in creating 
a model that demonstrates the distribution of SM3 CalQDs 
is capturing physiological differences due to the extent of 
tumor growth. In the early stages of IBC, the cancer cells are 
localized within the breast tissue. During the course of the 
disease, 70% of patients with IBC develop a distant metas-
tasis, suggesting the need to model different dynamics for 
early-stage compared to late-stage IBC.2 Additionally, acute 
inflammatory response to cancer can cause the spleen to 
become enlarged.13 To demonstrate the dynamics of SM3 
CalQDs in both early and late-stage cancer as well as a 
healthy mouse, three distinct models will be created charac-
teristic of each stage.
METHODS
PBPK model
This PBPK model for the distribution of CalQDs in mice for 
use in IBC treatment is based on a priori physical laws and 
parameters. The organs included are those most relevant 
to CalQD distribution during the particular cancer phase 
being modeled. In both early-stage and late-stage cancer 
models, the plasma compartment behaves as the central 
compartment by which the QDs are carried to and from 
the other tissues. The treatment is modeled as an intrave-
nous injection, so the substance is directly inserted into the 
plasma compartment as system input. The lungs, spleen, 
liver, and kidneys are included as they are richly perfused 
organs and have been shown to preferentially accumulate 
the QDs tested by Schaefer et  al.8,10,12 As IBC generates 
a large immune response, the spleen compartment is also 
used to model the influence of splenomegaly often seen 
in patients with cancer. The liver receives blood flow from 
the spleen and is vital for clearance and breakdown of the 
CalQDs in the body via biliary secretion.14,15 Additionally, 
the lungs are one of the most common sites for early IBC 
metastasis. Previous studies have shown that QDs in-
jected intravenously in mice localize in the liver, kidneys, 
and spleen.10,14 The “other” compartment was included as 
a lumped compartment for tissues not explicitly mentioned.
In late-stage models, a tumor compartment is included 
in parallel to the other organs to represent delocalized 
tumor tissue throughout the body due to metastasized 
tumors. In contrast, in the early-stage model, a tumor is 
housed in a compartment parallel to the breast so that it 
is surrounded by breast tissue. These organs were con-
nected according to their vascular connections in the 
human body (Figure 1).
Assumptions
The concentration of CalQDs in each compartment in the 
model was based on the dynamics of a continuous-stirred 
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tank reactor that is well mixed and perfusion  limited. The 
well-mixed assumption states that each organ or tissue re-
gion is homogeneous, with immediate mixing such that the 
inlet flow concentration instantaneously equilibrates with 
the concentration in the tank and efflux. The ubiquity of cap-
illaries in the body and the well-defined uniform exchange 
of QDs across these capillaries validate this assumption. 
Furthermore, the interstitial spaces of most organs tend to 
be uniform such that the concentration of substances en-
tering/exiting the bloodstream is the same across the organ. 
Because the blood stream contains uniformly mixed QDs, 
the organs do as well, each according to their diffusion and 
perfusion properties. The perfusion-limited (or flow-limited) 
assumption states that diffusion is limited by regional blood 
flow into the capillaries of an organ or tissue. A corollary 
from this is that tissue membranes offer no significant re-
sistance to molecular flow relative to the blood flow; dif-
fusion across any membrane is very fast compared with 
blood transport. The perfusion-limited assumption is akin 
to the quasi-steady-state approximation used in chemical 
engineering kinetics. This is a valid assumption based on 
the small size of CalQDs and minimal interactions with the 
tissue membranes.11
Parameter selection
The main parameters of interest to construct this PBPK 
model are the physiological parameters of our organism of 
interest, the biophysical behavior of our substance of in-
terest, and the interactions between the two in the form of 
partition coefficients. Fixed parameters of this model are 
compartment volumes and volumetric flowrates, whereas 
partition coefficients were varied among the healthy, ear-
ly-stage, and late-stage models.
Organ masses can be found in literature for a multitude of 
organs and organisms as a fraction of body weight (BW).16,17 
Schaefer et  al.10 used female mice between the ages of 
13–16 weeks, which have a mass of ~ 22.0 g.16,17 Knowing 
the BW of the mouse, organ masses can be determined 
using the mean percent BW of each organ. From organ 
masses, organ volumes can be determined via the specific 
gravity of each organ. For the majority of organs or tissue 
regions, a specific gravity of 1.0 can be assumed as they are 
generally in this range (1.02–1.06) because they are com-
posed primarily of water.15,18 There are a few notable excep-
tions: marrow-free bone has a density of 1.92 g/cm3, and 
the density of adipose tissue in mice is 0.916 cm3/100 g BW. 
To determine the mass of adipose in a mouse, the following 
equation can be used19:
Excluding the adipose and bone, the rest of the “other” 
compartment volume was determined using a specific 
gravity of 1.0. These three were then added for the lumped 
“other” compartment. Compartmental volumes for the 
model are shown in Table 1.
For a 22.0-g mouse with late-stage IBC, we used the 
tumor measurement given by Schaefer et al.10 This value 
was also used to approximate the early-stage tumor—a 
small error considering the small size of the tumor—
whereas the breast tissue BW was based on the weight 
of mammary glands reported by Fisher et  al.20 In the 
early-stage model, the breast compartment was created 
(1)(%BW)=0.0199(BW)+1.664
Figure 1 Physiologically-based pharmacokinetic connectivity for healthy, nontumor case (left), early-stage tumor (middle), and late-
stage tumor (right).
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by subtracting the volume for the breast tissue from the 
“other” organ compartment while maintaining a constant 
volume for the other organs.
The blood flow rate to each tissue region is given as a 
fraction of total cardiac output. The total cardiac output for 
our 22.0 g female mouse can be estimated from the follow-
ing equation where BW is given in kilograms19:
From the mean percent cardiac outputs, blood flow to 
each organ can be determined. Additionally, the flow rate 
to the tumor is based on previously measured tumor blood 
flow rate scaled to our tumor size.21 Compartmental volu-
metric flow rates are shown in Table 1.
QDs are injected intravenously into the organism, so the 
input to the model is a pulse into the plasma compartment. 
Effectively, this behaves as the plasma compartment start-
ing with an initial concentration based on the dosage and 
distributing to the rest of the body as time progresses. 
The sink for QDs is from the liver compartment as bili-
ary excretion, which takes the form of a first-order kinetic 
degradation of concentration with time. The following esti-
mation for the first-order clearance rate constant was pre-
viously validated from experimental data for QD 705.14 The 
value is very small because QD clearance from the body 
is slow with significant concentrations still measured even 
28 days after intravenous injection.
A partition coefficient is the equilibrium tissue-to-blood 
partition coefficient, a proportionality constant relating the 
tissue concentration of a substance X to the outgoing venous 
concentration. In the perfusion-limited case, it describes the 
ratio of the total tissue concentration of a substance X to its 
concentration in the outgoing blood flow. In practice, partition 
coefficients are approximated by the empirical equilibrium 
partition coefficient, which effectively lumps all processes 
that alter tissue extraction together in one term and is esti-
mated experimentally using in vitro experimentation.18 Due 
to the novelty of the QDs in this model, experimental partition 
coefficients do not yet exist, so estimation will be used going 
forward based on measured QD intensities (Table 2).10,11
Some partition coefficients are available for a similar QD 
(Table S1)14; assuming that conjugating calcitriol to QDs does 
not significantly affect the distribution of QDs in tissue we can 
use these values as a starting point. The initial partition coeffi-
cient estimates for the tumor compartment were based on the 
QD in question, with a low value used for the untargeted QDs 
and a much higher value used for targeted QDs, to consider the 
preferential attraction of SM3 CalQDs to IBC tumor cells that 
is expected due to the conjugated SM3 MUC1 antibodies.10
System of equations
The equations for the compartments are mass flow bal-
ances across homogeneous, well-stirred tissues with influx 
and efflux. Blood flows at the same volumetric flow rate, Q, 
(2)Cardiac output (L∕min)=0.275(BW)0.75
(3)kelim=1.0×10
−6 hr−1
Table 1 Compartmental volume and blood plasma volumetric flow 
rate parameters
Compartment Volume (mL)
Volumetric flow rate 
(mL/hour)
Blood plasma 1.078 944.3
Lungs 0.1606 4.713
Kidneys 0.3674 85.77
Spleen 0.077 (0.154) 18.85
Liver 1.208 132.9
Breast 1.05 22.79
Tumor 0.08 1.766
Other 55.76 677.5
Compartmental volumes and volumetric flowrates were calculated from 
literature for a 22-g mouse.14,15 The volume of the enlarged spleen case is 
shown in parenthesis. The tumor compartment volume and blood plasma 
flow rate were kept the same between the early-stage and late-stage mod-
els, so the values are an overestimate for the early-stage model.
Table 2 Mean pixel intensity of QDs in organs of mice with no tumor and with late-stage tumor
QD Organ
No tumor Late-stage tumor
Intensity Error (%) Intensity Error (%)
ConQD Kidney 10.40 10.22 12.54 17.52
Liver 16.23 22.20 14.85 16.91
Lung 4.66 16.21 8.22 2.24
Spleen 12.73 9.08 26.43 11.21
CalQD Kidney 11.01 9.14 15.15 20.58
Liver 20.38 12.99 20.15 31.96
Lung 3.16 8.07 7.59 5.27
Spleen 10.99 10.45 21.46 20.06
SM3 CalQD Kidney 10.47 12.67 11.57 17.98
Liver 17.18 6.91 18.12 8.22
Lung 5.01 16.57 7.46 12.94
Spleen 9.87 11.70 17.92 8.14
CalQD, calcitriol quantum dot; ConQD, control (unconjugated) QD; SM3, Mucin-3 antibodies; QDs, quantum dots.
Mice with and without SUM149 inflammatory breast cancer tumors were injected with SM3 CalQDs, CalQDs, or ConQDs, and after 4 days florescent images 
were taken. The mean pixel intensity values were reproduced with this model by fitting partition coefficient values with a residual sum of squares minimiza-
tion.10 The intensities reported for the late-stage tumor were also used for the early-stage model.
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into and out of each constant compartment volume, V. The 
change in concentration with respect to time, Ċ, is equiva-
lent to the blood flow rate divided by the constant volume, 
all multiplied by the concentration gradient across the com-
partment. The gradient can be represented by the change in 
concentration of a substance in the inflow (arterial concen-
tration) compared with the outflow (venous concentration) 
due to distribution into the tissue. Additionally, an organ may 
have a sink or source, which will be represented here as a 
rate, R. Overall, this gives Eq. 4 for a single organ system.
Because we are interested in the concentration in the actual 
tissue rather than in the circulatory system, we will utilize the 
partition coefficient, P, the ratio of concentration of substance 
X in the tissue, c, to the incoming plasma concentration of sub-
stance X, co. For compartments connected to the plasma com-
partment, co is the venous concentration of the substance.
Substituting this into Eq. 4, we have the following equa-
tion to describe a single organ system:
Thus, for our healthy, nontumor system, containing the 
kidneys, liver, lungs, spleen, and plasma, with pulse input 
and excretion from the liver following first-order kinetics, 
we have the following set of differential equations with con-
served volumetric flowrate:
For the late-stage IBC case, the blood plasma compart-
mental balance and overall molar flow equations change, as 
well as the addition of a tumor equation. All other equations 
remain the same.
In the case with an early-stage tumor, the equations re-
main the same except for those pertaining to the tumor and 
blood. In addition, a breast compartment is added, making 
these equations as follows:
Equations were solved simultaneously using the built-in 
function ode23s on MATLAB R2017b. All above parame-
ters were constants found in literature except for the par-
tition coefficients, which were varied from their original 
estimations such that model results match experimental 
florescence data 4 days after dosage in Table 2 via a re-
sidual sum of squares minimization. As there are no fluo-
rescence data available for mice with early-stage IBC, the 
data for the late-stage model are used. This results in sig-
nificant error as the difference between the early-stage and 
late-stage models is only the change in connectivity. In the 
unhealthy, tumor cases, the model estimates the concen-
tration of QDs in tumor tissue as well. In addition, the effect 
of doubling the volume of the spleen on the organ partition 
coefficients and model results was analyzed. Although we 
will look at an increased spleen volume, we maintain the 
spleen blood flow rates.
RESULTS
Partition coefficients
There is a lack of experimental information available on 
the QDs in question as the proposed treatment is a recent 
and novel development. The QDs have been found to ac-
cumulate in specific tissues,8,10,12 so the partition coeffi-
cient for the “other” compartment was assumed to be 1. 
For all additional compartments, the partition coefficients 
(4)Ċ=
Q
V
(ci−co)+R
(5)P=
c
co
(6)Ċ= Q
V
(ci−
c
P
)+R
(7)
Ċplasma(p)=
(
1
Vp
){[(
QkCk
Pk
)
+
(
Qli+Qs
) Cli
Pli
+
(
QlCl
Pl
)
+
(
QoCo
Po
)]
− (Qtotal)Cp
}
(8)Qtotal=Qkidney+Qliver+Qspleen+Qlung+Qother
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(
Qk
Vk
)[
Cp−
Ck
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]
(10)Ċlung(l)=
(
Ql
Vl
)[
Cb−
Cl
Pl
]
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(
Qs
Vs
)[
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Ps
]
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(
1
Vli
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Cs
Ps
− (Qli+Qs)
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−kCli
]
(13)Ċother(o)=
(
Qo
Vo
)[
Cp−
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]
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(
1
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)
+
(
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+
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}
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(
Qt
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]
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used for each model are shown in Table 3, with the val-
ues for the enlarged spleen case shown in Table S2. In 
each case, tumor partition coefficients are much higher 
for the SM3 CalQDs compared with the untargeted QDs. 
However, tumor compartment partition coefficients are 
significantly sensitive to the initial estimate used as the 
compartmental volume is very small and the experimen-
tal concentration in the cancer cells for each is unknown. 
Additionally, partition coefficients for the kidney, liver, 
spleen, and lung compartments all increase under the en-
larged spleen case. For SM3 CalQDs, this led to a lower 
concentration in the tumor compartment, especially for 
the early-stage case.
Model results
Normalized time-concentration graphs for SM3 CalQDs 
for each model (no tumor, early-stage tumor, and late-
stage tumor) are shown in Figure 2. The maximum con-
centration of SM3 CalQDs in the tumor compartment is 
~ 20% higher for the late-stage model than the early-stage. 
Additional plots for untargeted CalQDs and unconjugated 
control QDs (ConQDs) are in Figures S1 and S2. Figure 
S3 is a reproduction of Figure 2 extended to 4 days. These 
results show a very fast convergence to a steady concen-
tration in each compartment except the tumor, which has 
a slower increase due to the relatively small blood plasma 
flow rate to the compartment. In the early-stage case, the 
breast compartment QD concentration remains low in 
comparison with the tumor compartment due to the large 
disparity in their partition coefficients and relatively small 
size of the tumor compartment. QD concentrations in the 
spleen and kidneys quickly peak before decreasing and 
redistributing some of the QDs to other compartments. 
Other tissue regions exhibit a monotonic increase over the 
entire time span.
In Figure 3, QD concentration profiles in the spleen com-
partment for the normal and enlarged spleen cases are com-
pared in the late-stage model. The enlarged spleen volume 
is used as an example of a potential application of the model 
to describe changes in QD distribution due to a common 
symptom of cancer. Of note is the loss of an initial peak be-
fore reaching a relatively steady-state value; this behavior 
represents a relative loss in blood flow to the spleen. These 
dynamics are mirrored in the early-stage case. Other com-
partmental time-concentration profiles are qualitatively unaf-
fected by spleen volume.
Table 3 Compartmental partition coefficient values for the three models
Compartment
No tumor Early-stage tumor Late-stage tumor
ConQD CalQD SM3 CalQD ConQD CalQD SM3 CalQD ConQD CalQD SM3 CalQD
Kidney 32.7 46.9 34.8 45.1 91.2 59.1 41.7 74.1 46.6
Liver 50.9 86.3 56.8 53.4 121.2 92.6 49.3 98.3 72.8
Spleen 40.0 46.9 32.8 95.0 129.1 91.5 88.0 105.0 72.3
Lung 14.6 13.4 16.6 29.6 45.7 38.1 27.3 37.1 30.1
Tumor — — — 28.6 45.5 97.4 24.9 23.8 98.1
Breast — — — 2.67 1.71 1.83 — — —
CalQD, calcitriol quantum dot; ConQD, control (unconjugated) QD; SM3, Mucin-3 antibodies.
Partition coefficients were found through a residual sum of squares minimization with experimental QD concentration data. The partition coefficient for the 
other compartment for each model was assumed to be 1.
Figure 2. SM3 calcitriol quantum dot healthy (left), early-stage (middle), and late-stage (right) time-concentration results for regular 
spleen size. Concentration values are normalized by the initial concentration in the plasma compartment. The results are shown only 
to 4 or 12 hours, as concentrations afterward are steady state and scaling the figure would obscure these dynamics. SM3, Mucin-3 
antibodies.
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DISCUSSION
Overall, it was shown that a PBPK model can be used 
to describe the behavior and distribution of QDs both in 
healthy and tumorous mice. Although partition coefficient 
data for any of the QDs in question are unavailable, es-
timated partition coefficients were found that produced 
simulated data consistent with that found experimentally. 
This model generates continuous time-concentration 
data of QDs in several tissue regions, which can be useful 
for quantifying short-term and long-term behavior of the 
various QDs in each tissue region.
In all simulations, no QD concentration exceeds the ini-
tial dosage, so hypercalcemia due to extreme local concen-
trations should not be a concern. However, changes such 
as experimentally determined partition coefficients or more 
aggressive dosing regimens could lead to larger spikes in 
compartmental QD concentration. Of special interest are 
maximum QD concentrations in the spleen, liver, and kid-
neys because these organs are richly perfused and have 
been shown to accumulate QDs in mice.8,10,12 Toxic tissue 
concentration of QDs could remain excessive for weeks, so 
it is important to be able to predict and prevent this.
When partition coefficients are estimated with experimen-
tal tissue concentration data, any partition coefficient not 
explicitly validated by the data will cause significant error in 
the resulting time-concentration values. In this case, assum-
ing the “other” compartment has a partition coefficient of 1 
is a substantial source of error, as the compartment is most 
of the volume in the system and receives over two-thirds of 
the total blood flow. This error is easily observable due to the 
large differences between the partition coefficients in Table 3 
for the same organ. In this way, the partition coefficients re-
ported are empirical and cannot be deconvoluted to find the 
true physiological partition coefficient. Thus, interpretation 
of a larger partition coefficient for a different QD or different 
model as meaning a higher affinity for the given QD is only true 
within each instance of the simulation. That is, only the rela-
tionship between partition coefficients for each compartment 
in a given model can be considered. In particular, the tumor 
compartment partition coefficient is quite variable and cannot 
be determined with much certainty without further information. 
Moreover, the experimental QD concentration measurements 
used to fit the partition coefficients may contain errors whose 
effects cannot be accounted for in a straightforward manner. 
Not enough data exist to determine standard error at this time; 
as more experimental data become available, adjustments 
can be made to this framework.
For this model to be quantitatively predictive, further 
experimental data are needed to estimate the partition 
coefficients. The best option is conducting in vitro exper-
iments to determine physiological partition coefficients22 
so that the model could be developed fully a priori rather 
than based on experimental concentration data. Currently, 
the model presented is limited because the data used to 
estimate the partition coefficients do not contain informa-
tion about the short-time dynamics of QD distribution. The 
data  are for QD concentration 4  days after dosage, yet, 
in this model, most dynamics happen on the time scale 
of hours. This error is seen in the results, where QD con-
centrations peak earlier than during the second day, as 
observed by Schaefer et al.10
A valuable improvement to this model is the incorporation 
of the lymphatic system, which plays an important role in 
IBC. In addition to blood flow, the model would include lymph 
flow that comes from each compartment, goes through 
a lymph node compartment, and is emptied into venous 
blood. IBC tumor emboli often travel through dermal lym-
phatic vessels causing distant metastases.3 Symptoms are 
typically observed after the initial tumor has metastasized, 
so it is valuable to consider the lymphatic system as it is sys-
tematically interconnected with the network of metastases. 
In addition, decoupling distribution by blood flow and lymph 
flow would help explain the preference of QDs to organs that 
are heavily involved in lymph flow (e.g., lungs) in tumorous 
mice, even in the case of untargeted QDs.10 Furthermore, 
the model could consider tumor metastasis with the addition 
of a tumor subcompartment for each tissue and delump-
ing tissues particularly susceptible to metastasis from the 
“other” compartment like bone and skin. Then, tumor emboli 
could be represented by concentration in blood and lymph. 
More ambitiously, the presence of agents other than cal-
citriol that affect IBC cells, such as TGFβ, which plays a role 
in IBC emboli formation as well as IBC cell clustering during 
movement through the body, could supplement this tumor 
metastasis model.3 Expanding the model in this way allows 
for real-time quantitative simulation of IBC treatment, with 
tumor growth and QD distribution occurring simultaneously.
Progress in understanding disease on the molecular level 
has led to an increased popularity of personalized medicine, a 
strategy where treatment depends on models that characterize 
and differentiate patients based on their individual characteris-
tics. The classic trial-and-error approach to treating disease has 
many shortcomings, notably that the physician or experimen-
talist must make an educated guess about which treatment will 
Figure 3 Late-stage spleen compartment concentration for 
SM3 calcitriol quantum dots (CalQDs; red), CalQDs (purple), 
and ConQDs (blue) with corresponding enlarged spleen 
results (dotted). Results for the early-stage model are similar. 
Concentration values are normalized by the initial concentration 
in the plasma compartment. ConQD, control (unconjugated) QD; 
SM3, Mucin-3 antibodies.
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be most effective, as well as when to administer it and how 
much to give the patient. Allometric scaling of the compartment 
volumes can be used to adapt this model for use in predicting 
appropriate dosages for clinical or experimental trials with QD 
IBC treatments on other animals.23 Adaptation of this model for 
humans should be accompanied by specific emphasis placed 
on accurate modeling of the breast compartment. Currently, 
the model lacks enough experimental data to provide reliable 
QD concentration estimates. However, further experimental 
validation of the model would allow for dynamic quantitative 
prediction of QD concentrations, which when coupled with a 
well-developed therapy program could be a powerful tool for 
fighting IBC. For instance, the model can be used to determine 
peak concentrations as well as area under the curve (AUC) ex-
posures, which are crucial factors in designing chemotherapy 
regimens and dosing schedules. This translates to prediction 
of the optimal SM3 CalQD dosage amount and frequency to 
provide a target exposure of the QDs based on how developed 
the IBC is, while avoiding hypercalcemia in other tissues.
This PBPK model has been constructed and validated for 
multiple QDs, notably SM3 CalQDs, which are of interest for 
IBC treatment. SM3 CalQDs provide a targeted calcitriol treat-
ment for IBC cells, which is important to mitigate cancerous 
effects of the tumor cells while allowing for live cell direct 
imaging and avoiding hypercalcemia in patients. Further in 
vitro analysis of the QDs is recommended so that currently 
estimated parameters can be replaced by physiologically ac-
curate values to complete the top-down model. This model 
has potential as a predictive tool to guide or supplement both 
experimental and clinical endeavors in QD treatment of IBC 
with the hope that a more successful treatment is developed.
Supporting Information. Supplementary information accompa-
nies this paper on the Clinical and Translational Science website (www.
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